PharmaLundensis (PHAL) Q3 2025 earnings summary

Executive summary

• Net sales remained at 0 SEK for both the quarter and nine-month period compared to the previous year.

• Net loss after financial items increased to -1,686,220 SEK for the quarter and -5,203,352 SEK for the nine months, both higher than the prior year.

• The new Minievaporator device development progressed well, with deliveries expected to start in Q1 2026.

• Significant market interest in the Minievaporator from chemical industry companies.

Financial highlights

• Net loss per share was -0.03 SEK for the quarter and -0.09 SEK for the nine months, both worse than the previous year.

• Equity ratio as of September 30, 2025, was 44.2%.

• No revenue was generated; all income lines remained at 0 SEK.

• Cash and cash equivalents increased to 2,619,629 SEK as of September 30, 2025.

Outlook and guidance

• Capital is expected to last until spring 2026; further funding will be needed via Minievaporator sales or new share issues.

• The Minievaporator is anticipated to provide significant financial contributions starting next year.